Idiopathic urticaria
Conditions
Interventions
Four week-treatment with fexofenadine (120 mg/day) group
Untreatment observation group
Sponsors
West Japan Urticaria Therapy Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with idiopathic urticaria 1. Symptoms/signs free of urticaria for at least 48 hrs at the randomization 2. Symptom/signs are resolved in the period of 2-6 weeks from the onset of uritcaria 3. Not less than 20 years old (no upper limit) 4. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women or women of child bearing potential not using contraception 2. Patients with a history of hypersensitivity to fexofenadine hydrochloride 3. Patients who use medications that interfere with the efficacy evaluation (e.g., other antihistamines, drugs with anti-allergy action, systemic steroids etc.) 4. Others whom the physician judges are not suitable as subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative recurrence rate at 3 months after relief of urticaria symptoms (signs) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Cumulative recurrence rate at 4 and 8 weeks after the relief of urticaria symptoms(signs) 2. Safety | — |
Countries
Japan
Contacts
Public ContactMotoaki Inoue
Clinical Research Support Center Kyusyu Secretariat
Outcome results
None listed